series-b
Stage
1
Investors
About
Kobiolabs develops innovative microbiome-based therapeutics using AI-driven multi-omics analysis and microbe-based drug delivery systems, targeting immune, metabolic, and neurological diseases.
Explore Kobiolabs's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.